LuViva, which is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable, scans the cervix and identifies cancer and pre-cancer painlessly using the light as well as detects changes at the cellular levels by utilizing the company’s patented biophotonic technology.

In anticipation of the international market launch, the company is planning to meet with distributors who are interested in representing LuViva in select markets around the world.

Guided Therapeutics international sales manager Melissa White said the company is actively seeking to add qualified distributors to its growing LuViva sales network that have experience introducing the technology into the women’s health market.

"LuViva is attracting superior medical device distributors internationally due to its unique technology and business model which combines a highly valued device with a single-use disposable," White added.

"While the technology allows distributors to differentiate themselves from competitors, it also provides a viable solution to increasing healthcare quality while lowering healthcare costs in the countries where they operate.

"We look forward to meeting with companies who are interested in being a part of introducing LuViva to women around the world."